Browsing by Author "Bayoglu, Ibrahim Vedat"
Now showing items 1-4 of 4
-
Multicenter Epidemiologic Study on Hepatocellular Carcinoma in Turkey
Can, Alper; Dogan, Erkan; Bayoglu, Ibrahim Vedat; Tatli, Ali Murat; Besiroglu, Mehmet; Kocer, Murat; Dulger, Ahmet Cumhur; Uyeturk, Ummugul; Kivrak, Derya; Orakci, Zuat; Bal, Oznur; Kacan, Turgut; Olmez, Sehmus; Turan, Nedim; Ozbay, Mehmet Fatih; Alacacioglu, Ahmet (ASIAN PACIFIC ORGANIZATION CANCER PREVENTION, 2014)Background: Hepatocellular cancer (HCC) is one of the important health problems in Turkey, being very common and highly lethal. The aim of this study was to determine clinical, demographic features and risk factors. Materials ... -
Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors
Gumus, Mahmut; Bilici, Ahmet; Odabas, Hatice; Ustaalioglu, Bala Basak Oven; Kandemir, Nurten; Demirci, Umut; Cihan, Sener; Bayoglu, Ibrahim Vedat; Ozturk, Turkan; Turkmen, Esma; Urakci, Zurat; Seker, Mehmet Metin; Gunaydin, Yusuf; Selcukbiricik, Fatih; Turan, Nedim; Sevinc, Alper (SPRINGER, 2017)Background Currently, it is accepted that risk assessment of clinical stage I (CS I) nonseminomatous germ cell tumors (NSGCT) patient is mainly dependent on the presence of lymphovascular invasion (LVI). Initial active ... -
Outcomes of surveillance VS. adjuvant chemotherapy for patients with STAGE IA and IB NON-seminomatous testicular germ-cell tumors.
Bilici, Ahmet; Gumus, Mahmut; Odabas, Hatice; Kandemir, Nurten; Demirci, Umut; Cihan, Sener; Bayoglu, Ibrahim Vedat; Ustaalioglu, Bala Basak Oven; Ozturk, Turkan; Turkmen, Esma; Urakci, Zuhat; Seker, Mehmet Metin; Gunaydin, Yusuf; Selcukbiricik, Fatih; Turan, Nedim; Sevinc, Alper (AMER SOC CLINICAL ONCOLOGY, 2016)… -
XELOX Plus Bevacizumab vs. FOLFIRI Plus Bevacizumab Treatment for First-line Chemotherapy in Metastatic Colon Cancer: a Retrospective Study of the Anatolian Society of Medical Oncology
Duran, Ayse Ocak; Karaca, Halit; Besiroglu, Mehmet; Bayoglu, Ibrahim Vedat; Menekse, Serkan; Yapici, Heves Surmeli; Yazilitas, Dogan; Bahceci, Aykut; Uysal, Mukremin; Sevinc, Alper; Hacibekiroglu, Ilhan; Aksoy, Asude; Tanriverdi, Ozgur; Arpaci, Erkan; Inanc, Mevlude; Dane, Faysal; Ozkan, Metin (ASIAN PACIFIC ORGANIZATION CANCER PREVENTION, 2014)Background: XELOX plus bevacizumab (XELOX-Bev) and FOLFIRI plus Bevacizumab (FOLFIRI - Bev) treatments are an effective strategies patients with metastatic colorectal cancer (mCRC). The aim of this study was to compare ...
